{"brief_title": "Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy", "brief_summary": "This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (\u03b15\u03b21 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.", "condition": ["Melanoma", "Metastases"], "intervention_type": ["Drug"], "intervention_name": ["M200 (volociximab) in Combination with Dacarbazine (DTIC)"], "criteria": "Inclusion Criteria: - Males and females of at least 18 years of age with stage IV or unresectable stage III non-ocular melanoma who may have received 0 to 2 prior regimens for metastatic disease with a biological therapy or immunotherapy (e.g., IL-2 or interferon-alfa). - Measurable disease according to Response Criteria for Solid Tumors (RECIST). - Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1. - Estimated survival is greater or equal to 4 months. - Negative pregnancy test (women of childbearing potential only). - Pretreatment laboratory levels that meet specific criteria. - Signed informed consent, including permission to use protected health information. Exclusion Criteria: - Prior treatment with M200 or a5b1 inhibitors and murine or chimeric monoclonal antibodies. - Prior treatment with DTIC, temozolomide, or other chemotherapeutic regimens. - Known sensitivity to murine proteins or chimeric antibodies or other components of the product. - Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer). - Systemic biologic, immunotherapy, and/or radiation therapy within 4 weeks of the first dose of M200. - Documented central nervous system (CNS) tumor or CNS metastasis. - History of thromboembolic events and bleeding disorders within the past year. - Medical conditions that may be exacerbated by bleeding.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Metastatic melanoma", "mesh_term": ["Melanoma", "Antibodies, Monoclonal"], "id": "NCT00099970"}